BIO PLUS CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,480 KRW | -0.61% |
|
+1.25% | -5.68% |
| 24/01 | Elevance Health Offers Stronger-Than-Expected 2024 Earnings Outlook After Fourth-Quarter Beat | MT |
| 24/01 | Elevance Health Issues Upbeat 2024 Adjusted. Earnings Outlook After 4Q Revenue Gains | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 56.72B 41.75M 3.48B | Sales 2023 | 65.04B 47.87M 4B | Capitalization | 393B 289M 24.13B |
|---|---|---|---|---|---|
| Net income 2022 | 21.14B 15.56M 1.3B | Net income 2023 | 25.58B 18.83M 1.57B | EV / Sales 2022 | 5.82 x |
| Net cash position 2022 | 72.18B 53.13M 4.43B | Net cash position 2023 | 55.74B 41.03M 3.42B | EV / Sales 2023 | 5.18 x |
| P/E ratio 2022 |
18.8
x | P/E ratio 2023 |
15.9
x | Employees | - |
| Yield 2022 |
1.01% | Yield 2023 |
1.02% | Free-Float | 68.01% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.61% | ||
| 1 week | +1.25% | ||
| Current month | +0.62% | ||
| 1 month | -5.26% | ||
| 3 months | -9.50% | ||
| 6 months | -4.71% | ||
| Current year | -5.68% |
1 week
6 410.00
6 610.00
1 month
6 280.006 910.00
Current year
6 280.007 450.00
1 year
6 070.009 090.00
3 years
5 087.5010 750.00
5 years
5 087.5010 750.00
10 years
5 087.5010 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hyun-Kyu Jung
CEO | Chief Executive Officer | 67 | 01/13/01 |
Sung-Young Park
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/01 |
Min-Yup Lee
BRD | Director/Board Member | 52 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyun-Kyu Jung
CEO | Chief Executive Officer | 67 | 01/13/01 |
Sung-Young Park
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/01 |
Se-Yoon Lee
BRD | Director/Board Member | 65 | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 6,480 | -0.61% | 130,677 |
| 02/24/02 | 6,520 | +1.24% | 145,953 |
| 30/24/30 | 6,440 | -0.16% | 105,023 |
| 29/24/29 | 6,450 | +0.78% | 124,284 |
End-of-day quote Korea S.E., May 03, 2024
More quotes
BioPlus Co Ltd is a Korea-based company principally engaged in the medical device business. The Company is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.68% | 274M | |
| -3.78% | 88.14B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -9.12% | 11.97B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B |
- Stock Market
- Equities
- A099430 Stock